Biohaven Pharmaceutical (BHVN)
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncolog...
- Open
- 15.880
- High
- 16.340
- Low
- 14.940
- Prev. Close
- 16.120
- Volume
- 2.89M
- Turnover
- 44.96M
- Avg Price
- 15.568
- Bid/Ask Ratio
- --
- Amplitude
- 8.68%
- 52wk High
- 18.566
- Volume Ratio
- 1.60
- Turnover Ratio
- 2.48%
Biohaven Pharmaceutical Analyst Rating
View moreForecast & Rating
Aug 27, 2026Price forecast
$21.7341.03%
Forecast & RatingBuy
16analysts
- Strong buy56.25%
- Buy25.00%
- Hold12.50%
- Sell0.00%
- Strong sell6.25%
News
- Market Beat · Aug 27 at 11:00 AM
Biohaven (NYSE:BHVN) Shares Down 7.4% - What's Next?
- Pharmaceutical Technology · Aug 27 at 08:40 AM
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
- benzinga_article · Aug 26 at 12:41 PM
Why Is Biohaven Stock Soaring Wednesday?
- PUBT · Aug 26 at 04:52 AM
Delaware court enters USD 4 million judgment for Biohaven, Yale in trade secret case against RA Capital, Avilar
- prnewswire · Aug 26 at 04:31 AM
05:29 ETSK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
- StockTitan · Aug 25 at 05:36 PM
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy | BHVN Stock News
